deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)

versus placebo
ipilimumab alone vs. placebo 2 -4%-29%-

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer